The Multimillion-Pound ADHD Industry: A Private Equity Takeover
The healthcare sector has witnessed a surprising transformation, with private equity firms seizing control of ADHD clinics, a development that has sparked both concern and controversy. These firms are raking in substantial profits by providing assessment and treatment services to tens of thousands of NHS patients, a trend that has led to an unprecedented surge in ADHD spending, straining NHS budgets.
The NHS's reliance on private services for ADHD and autism diagnoses has resulted in an exponential growth in spending, with over half a million people in England facing long waits for assessments. The initiative called 'Right to Choose' grants these patients the legal right to opt for private assessments, and the NHS covers the costs. This has triggered a rapid expansion of private providers, many of which have caught the attention of private equity investors seeking quick returns.
Last year, the NHS funded 100,000 private ADHD assessments through the Right to Choose scheme, with most evaluations conducted online. Strikingly, over 80% of referrals to certain clinics led to ADHD diagnoses. Analysis by The Times reveals that three private-equity-backed providers of NHS ADHD services collectively generated annual gross profits of £31.5 million.
The NHS's expenditure on private ADHD companies skyrocketed to £128 million last year, up from £36 million two years prior. To curb spending, some local NHS bodies have imposed caps on funded assessments, a move that charities argue is detrimental to ADHD patients. The question arises: Are we overdiagnosing a generation with ADHD?
Key players in this market include ADHD360, offering an 'essential care package' of assessment and treatment via video calls for £1,740. Its turnover nearly doubled in a year to £22.5 million, with gross profits of £9.7 million, making it a lucrative venture. ADHD360 is owned by Keys Group, backed by private equity firm G Square Capital.
Psychiatry UK, another major provider, posted £53 million in revenue for the 2023-24 fiscal year, delivering thousands of ADHD assessments for the NHS. It is owned by Queen's Park Equity, a London-based private equity firm.
Critics argue that the Right to Choose scheme incentivizes private clinics to attract patients, forcing the NHS to foot the bill. David Rowland, director of the Centre for Health and the Public Interest, highlights the scheme's impact, stating that if the private sector can secure patients, the NHS is obligated to pay. He advocates for profit caps on private companies delivering NHS care, emphasizing the leakage of allocated funds for NHS improvements.
The spiraling costs of ADHD diagnosis are exacerbating financial pressures on integrated care boards (ICBs), the local health bodies commissioning NHS care. This has led some ICBs to halt new referrals for adult ADHD assessments, including under the Right to Choose initiative, due to budget constraints. Mark Pattison, CEO of Care ADHD, warns that delayed assessments may lead to emergency department visits and mental health crises.
Despite concerns, Rebecca Gray, mental health director, emphasizes the need for NHS leaders to prioritize those with the highest need for ADHD assessments, focusing on high-risk groups. The NHS acknowledges underdiagnosis, estimating 2.5 million people in England with ADHD, with 297,000 taking medication, a significant increase from 81,000 a decade ago.
The debate surrounding ADHD diagnosis and treatment continues, with private equity's role raising questions about the balance between profit and patient care.
